Mission Wealth Management’s Alaunos Therapeutics TCRT Stock Holding History

Mission Wealth Management’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-106	Closed	-$61K	–	336
2019 Q1	$61K	Hold	106	–	–	0.01%	315
2018 Q4	$30K	Hold	106	–	–	﹤0.01%	275
2018 Q3	$51K	Hold	106	–	–	0.01%	281
2018 Q2	$48K	Sell	106 -8	-7%	-$5.07K	0.01%	264
2018 Q1	$67K	Hold	114	–	–	0.01%	234
2017 Q4	$71K	Hold	114	–	–	0.01%	228
2017 Q3	$105K	Hold	114	–	–	0.02%	205
2017 Q2	$106K	Hold	114	–	–	0.02%	187
2017 Q1	$108K	Buy	+114	New	+$106K	0.02%	187
2016 Q3	–	Sell	-114	Closed	-$94K	–	170
2016 Q2	$94K	Hold	114	–	–	0.03%	157
2016 Q1	$127K	Sell	114 -19	-14%	-$19.4K	0.03%	154
2015 Q4	$166K	Hold	133	–	–	0.05%	137
2015 Q3	$180K	Buy	133 +36	+37%	+$59.4K	0.05%	130
2015 Q2	$156K	Buy	+97	New	+$151K	0.05%	133

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Mission Wealth Management's TCRT Position: Q2 2019 in Review

Mission Wealth Management sold out of Alaunos Therapeutics (TCRT) in Q2 2019, closing a stake of 106 shares — an estimated $61K sold.

Mission Wealth Management first reported a position in TCRT in Q2 2015 and held it in 14 quarters. The position peaked at $180K in Q3 2015. 140 funds tracked by Wall St. Rank hold TCRT as of Q2 2019.

Mission Wealth Management reported no remaining Alaunos Therapeutics position as of Q2 2019 after selling out during the quarter.
Mission Wealth Management sold 106 Alaunos Therapeutics shares in Q2 2019, an estimated $61K.
Mission Wealth Management first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 14 quarters.
Mission Wealth Management's Alaunos Therapeutics position peaked at $180K in Q3 2015.
140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2019.

Based on Mission Wealth Management's 13F filing for Q2 2019, filed 9 Aug 2019.